홈 › 급성 골수성 백혈병 › 캔자스
캔자스의 급성 골수성 백혈병 임상 시험
급성 골수성 백혈병 관련 연구 20개가 캔자스 내 여러 지역에서 참여자를 모집하고 있습니다.
캔자스의 도시
공식 연구 텍스트(영어)
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- 외 1개
피험자 모집 중2상
18세 ~ 59세 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Kansas Clinical Research Center, Fairway
- HaysMed, Hays
- University of Kansas Cancer Center, Kansas City
- 외 7개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05564390Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06672146Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- 외 2개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- 외 1개
피험자 모집 중2상
18세 ~ 59세 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT05554406Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Kansas City KS-KUMC, Fairway
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT06652438Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
- Veteran Administration Eastern Kansas Healthcare, Leavenworth
- 외 4개
피험자 모집 중관찰 연구건강한 지원자 환영
40세 ~ 75세 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT05334069Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Kansas City KS-KUMC, Kansas City
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 1. 업데이트됨 · NCT07223814A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- 외 1개
피험자 모집 중1상
18세 ~ 75세 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT05886049Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- The University of Kansas Cancer Center, Kansas City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 20. 업데이트됨 · NCT06001788Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- University of Kansas Cancer Center, Westwood
피험자 모집 중3상
18세 ~ 75세 · 모든 성별 · 2026. 7. 17. 업데이트됨 · NCT05429632A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Kansas, Westwood
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT01351545A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
- University of Kansas Medical Center Research Institute, Inc., Kansas City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 4. 13. 업데이트됨 · NCT06146257Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
- University of Kansas Cancer Center, Westwood
피험자 모집 중1상
18세 ~ 65세 · 모든 성별 · 2026. 3. 25. 업데이트됨 · NCT03533816A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Kansas Medical Center, Westwood
피험자 모집 중2상
18세 ~ 66세 · 모든 성별 · 2026. 3. 17. 업데이트됨 · NCT06859424A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- The University of Kansas Medical Center Research Institute, Fairway
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 3. 13. 업데이트됨 · NCT05735184Safety of MT-401-OTS in Patients With Relapsed AML or MDS
- KU Cancer Center, Kansas City
피험자 모집 중1상
65세 이상 · 모든 성별 · 2025. 12. 16. 업데이트됨 · NCT06552416APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
- University of Kansas, Fairway
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 5. 11. 업데이트됨 · NCT06634394Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- University of Kansas Cancer Center, Fairway
피험자 모집 중2상
18세 이상 · 모든 성별 · 2025. 3. 7. 업데이트됨 · NCT02781883Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
- University of Kansas Cancer Center, Fairway
피험자 모집 중1상
18세 이상 · 모든 성별 · 2020. 6. 9. 업데이트됨 · NCT04167696ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.